NeuroSense Therapeutics Ltd. Ordinary Shares
N/A
USD
N/A
N/A
...
Chart
Financials
Description
NRSN Company Description
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
NRSN Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view NRSN Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of NRSN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by NRSN's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of NRSN in WallStreetBets Daily Discussion
NRSN News
Recent insights relating to NRSN
CNBC Recommendations
Recent picks made for NRSN stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in NRSN
Corporate Flights
Flights by private jets registered to NRSN
Our Analysis